Veeva Systems (VEEV)
(Delayed Data from NYSE)
$216.45 USD
+3.80 (1.79%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $216.00 -0.45 (-0.21%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.45 USD
+3.80 (1.79%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $216.00 -0.45 (-0.21%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum D VGM
Zacks News
Here's Why You Should Invest in PRA Health (PRAH) Stock Now
by Zacks Equity Research
The CRO industry's bullish prospects currently make PRA Health (PRAH) a promising investment pick.
TransEnterix's MST Medical Buyout to Boost Senhance Platform
by Zacks Equity Research
TransEnterix (TRXC) acquires Israel-based MST Medical, which will boost surgeons' effectiveness and make procedures quick and error-free.
Veeva (VEEV) Up 16.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.
Abbott Banks on New Approvals and Buyouts, Competition Rife
by Zacks Equity Research
Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
Cerner Integrated Platform Implemented by Spectrum Health
by Zacks Equity Research
Spectrum Health selects Cerner's (CERN) Cerner Integrated Platform to treat psychological disorders.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
Veeva's Vault CDMS to Unify Clinical Data in Single Platform
by Zacks Equity Research
Veeva's (VEEV) cloud-based applications' market prospects bright.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.
Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Veeva Gains as MD&D Companies Pick Its Cloud-Based Services
by Zacks Equity Research
Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.
3 Cloud-Powered MedTech Stocks to Buy Right Now
by Nabaparna Bhattacharya
Here we take a look at three MedTech companies that are likely to make big business banking on cloud technologies.
Earnings Estimates Moving Higher for Veeva Systems (VEEV): Time to Buy?
by Zacks Equity Research
Veeva Systems (VEEV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Here's Why You Should Invest in Veeva (VEEV) Stock Right Now
by Zacks Equity Research
Strong fundamentals and a solid Q2 aid Veeva (VEEV).
Is Veeva Systems (VEEV) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Time to Focus on Veeva Systems (VEEV) for Strong Earnings Growth Potential
by Zacks Equity Research
Veeva Systems (VEEV) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Veeva (VEEV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.
Veeva Systems (VEEV) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 14.71% and 2.92%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Segmental Growth Boost Veeva Systems' (VEEV) Q2 Earnings?
by Zacks Equity Research
Veeva Systems' (VEEV) Q2 results to benefit from growing demand for cloud-based and vault applications, new product launches, industry focus approach along with international expansion.
Veeva Systems' Development Cloud Platform Picked by Idorsia
by Zacks Equity Research
Switzerland's Idorsia implements Veeva Systems' (VEEV) Development Cloud. Veeva Systems gains foothold in Europe.
Why is Veeva Systems (VEEV) Up 8.3% Since Its Last Earnings Report?
by Zacks Equity Research
Veeva Systems (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: 3M, Altria, Stryker, UnitedHealth and Veeva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 3M, Altria, Stryker, UnitedHealth and Veeva